setting up for the big finish.....$, page-10

13 April 2005
Outstanding Increase in USA Sales
The Directors of Medical Monitors Limited (ASX: MDM) are pleased to advise that
Primedical International (Primedical) has placed an order for a further 20,000 ECG
monitoring units, in addition to the 10,000 units already announced. This will generate
more than USD$1,000,000 (AUD$1,300,000) in sales revenue to MDM over the next
three to six months.
Primedical is the exclusive holder of license and distribution rights for MDM products and
service for the USA. Medical Monitors has a direct benefit from both the manufacture and
supply of devices (the suPER) and a royalty stream from Primedical, which is estimated
at USD $300,000 (AUD$390,000).
Primedical’s USA-based ECG monitoring business has significantly exceeded the
expectations in its Business Plan for the first year of operation. Further sales are
anticipated through secured contracts, to supply ECG units and monitoring service to a
number of major medical clinics across the USA. Medical Monitors’ technology and
service model remains superior to the current market offerings in transtelephonic
(telephone transfer) cardiac monitoring
“This order into the largest ECG monitoring market confirms that Medical Monitors’
unique products and services are world class. We are very confident of exponential
growth in sales over the coming year, as MDM’s solution is able to reach the total
market”, said Dr Allan Shell, Managing Director.
“The take-up rate of our product has created a sales surge beyond our expectations and
represents more than 500% of the original budget for this financial year”, added Dr Shell.
MDM is well placed to take a substantial share of the lucrative US arrhythmia monitoring
market, estimated to be valued at approximately USD$550 million per annum. This
technology allows doctors to remotely monitor the cardiovascular health of their patients
and has already been granted United States Food and Drug Administration (FDA)
registration to enable marketing and sales.
For further information, please contact Dr Allan Shell on (02) 9344